PE20090608A1 - Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometrosis con simultanea reduccion de los efectos colaterales terapeuticos, asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo - Google Patents

Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometrosis con simultanea reduccion de los efectos colaterales terapeuticos, asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo

Info

Publication number
PE20090608A1
PE20090608A1 PE2008001424A PE2008001424A PE20090608A1 PE 20090608 A1 PE20090608 A1 PE 20090608A1 PE 2008001424 A PE2008001424 A PE 2008001424A PE 2008001424 A PE2008001424 A PE 2008001424A PE 20090608 A1 PE20090608 A1 PE 20090608A1
Authority
PE
Peru
Prior art keywords
congenital
reduction
gestagens
methyltetrahydrofolate
combination
Prior art date
Application number
PE2008001424A
Other languages
English (en)
Inventor
Christian Seitz
Annemarie Wasserall
Konstanze Diefenbach
Kristina King
Holger Zimmermann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090608A1 publication Critical patent/PE20090608A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMBINACION DE DE GESTAGENOS 17-ALFA-CIANOMETIL-17-BETA-HIDROXIESTRA-4,9-DIEN-3-ONA CON (6S)-5-METILTETRAHIDROFOLATO CARACTERIZADO POR UNA DOSIS DIARIA DE 0,4-1mg DE (6S)-5-METILTETRAHIDROFOLATO.DICHA COMPOSICION ESTA PRESENTE EN FORMA DE COMPRIMIDOS, CAPSULAS, GRAGEAS, OBLEAS, SUPOSITORIOS, ENTRE OTROS SIENDO UTILES EN EL TRATAMIENTO DE MALFORMACIONES CONGENITAS Y COMPLICACIONES AL INICIO DE UN EMBARAZO TALES COMO TUBO NEURAL, FIGURAS PALATINA, DE LABIOS Y DE MANDIBULA, DESPRENDIMIENTO DE PLACENTA Y ABORTO
PE2008001424A 2007-08-24 2008-08-22 Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometrosis con simultanea reduccion de los efectos colaterales terapeuticos, asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo PE20090608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07016642A EP2027855A1 (de) 2007-08-24 2007-08-24 Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität

Publications (1)

Publication Number Publication Date
PE20090608A1 true PE20090608A1 (es) 2009-06-12

Family

ID=38846909

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001424A PE20090608A1 (es) 2007-08-24 2008-08-22 Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometrosis con simultanea reduccion de los efectos colaterales terapeuticos, asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo

Country Status (17)

Country Link
EP (2) EP2027855A1 (es)
JP (1) JP2010536808A (es)
KR (1) KR20100047872A (es)
CN (1) CN101784271A (es)
AR (1) AR070023A1 (es)
AU (1) AU2008291406A1 (es)
BR (1) BRPI0815756A2 (es)
CA (1) CA2696030A1 (es)
CL (1) CL2008002485A1 (es)
EA (1) EA201000338A1 (es)
MX (1) MX2010002190A (es)
PA (1) PA8793901A1 (es)
PE (1) PE20090608A1 (es)
TW (1) TW200930377A (es)
UY (1) UY31306A1 (es)
WO (1) WO2009027003A1 (es)
ZA (1) ZA201002035B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874806A (zh) * 2009-04-29 2010-11-03 北京本草天源药物研究院 一种地诺孕素固体制剂
CN108379226B (zh) * 2018-05-28 2019-11-29 上海市计划生育科学研究所 氯地孕酮自微乳组合物、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CA2316303A1 (en) 1997-12-26 1999-07-08 Masaki Nakamura Suppressing agent of angiogenesis, containing dienogest as effective ingredient
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
DE102005053771A1 (de) * 2005-11-09 2007-05-10 Grünenthal GmbH Darreichform zur hormonalen Kontrazeption

Also Published As

Publication number Publication date
CL2008002485A1 (es) 2009-11-20
JP2010536808A (ja) 2010-12-02
EA201000338A1 (ru) 2010-08-30
AU2008291406A1 (en) 2009-03-05
UY31306A1 (es) 2008-11-28
EP2194978A1 (de) 2010-06-16
EP2027855A1 (de) 2009-02-25
AR070023A1 (es) 2010-03-10
TW200930377A (en) 2009-07-16
MX2010002190A (es) 2010-03-17
CA2696030A1 (en) 2009-03-05
CN101784271A (zh) 2010-07-21
KR20100047872A (ko) 2010-05-10
ZA201002035B (en) 2012-09-26
PA8793901A1 (es) 2009-04-23
WO2009027003A1 (de) 2009-03-05
BRPI0815756A2 (pt) 2015-02-18

Similar Documents

Publication Publication Date Title
TW200718689A (en) 2-Amino-quinazolin-5-ones
GT200000168A (es) Compuestos farmaceuticamente activos.
HK1166263A1 (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
ECSP14030098A (es) Formas cristalinas de un modulador del receptor androgénico
UY33029A (es) Antagonistas de espiro-oxindol de mdm2
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
BR112012027600A2 (pt) aplicador melhorado para uma composição adesiva para tratamento de lavatório
AR054123A1 (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
AR075369A1 (es) Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.
NZ600907A (en) Progestin/estradiol transdermal gel
CO6630107A2 (es) Formas de dosificación sólidas orales con dosis muy bajas para hrt
IL180575A0 (en) The use of memantine for the preparation of a medicament for the adjunctive treatment to atypical antipsychotics in schizophrenia patients
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
AR066312A1 (es) Uso de glucoproteinas de mucina en combinacion con agentes terapeuticos para tratar lesiones epiteliales y trastornos por deterioro de la funcion de la mucina
BR112013025878A2 (pt) composição farmacêutica e método para produzir uma composição farmacêutica
CL2012001596A1 (es) Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva.
RU2009120988A (ru) Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
ECSP109960A (es) Gel conteniendo pirfenidona
AR061959A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
IN266731B (es)
PE20090608A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para la terapia de la endometrosis con simultanea reduccion de los efectos colaterales terapeuticos, asi como reduccion del riesgo de malformaciones congenitas al comenzar un embarazo
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2012000478A1 (es) Formas cristalinas de 4,5,6,7-tetrahidro-11-metoxi-2-[(4-metil-1-piperazinil)metil]-1h-ciclopenta[alfa]pirrolo[3,4-c]carbazol-1,3(2h)-diona; composicion farmaceutica; y uso en el tratamiento de cancer.

Legal Events

Date Code Title Description
FD Application declared void or lapsed